Printer Friendly

QUIDEL REPORTS INCREASED SECOND QUARTER SALES AND EARNINGS

 QUIDEL REPORTS INCREASED SECOND QUARTER SALES AND EARNINGS
 SAN DIEGO, Oct. 28 /PRNewswire/ -- QUIDEL Corp. (NASDAQ: QDEL) today announced increased sales and net income for the second quarter fiscal year 1993 ended Sept. 30, 1992.
 Net sales for the quarter rose to $6.438 million, compared to net sales of $5.933 million in the same period last year. Increased worldwide sales of products under the QUIDEL label are reflected in the improved gross profit margin from 47.1 percent second quarter last year to 48.4 percent this current quarter. These profits allowed the company to increase its promotional support to its new Conceive(TM) product line and improve overall corporate profitability. Net income increased to $235,000, or $.01 per share, compared to net income of $168,000, or $.01 per share in the comparable period a year earlier.
 "We are pleased that worldwide sales of products under our own label continue to increase on a year-to-date basis and are responsible for the improvement of the gross profit margin," said Scott L. Glenn, chairman and chief executive officer of QUIDEL. "Development of new and innovative products sold through our domestic and international distribution channels remain our focus. We expect to continue our trend toward increased investment in research, product development and sales and marketing as we move forward in our strategy of building the company as a recognized global leader in the development and marketing of rapid diagnostic products."
 QUIDEL looks for sales of new products in conjunction with the expanded sales of current products to become the basis for future earnings growth. While overall product sales were slightly down for the six months on a year-to-year basis, growth of higher margin QUIDEL-labeled products remain the primary corporate objective. Over the long term, the company believes this strategy will result in increased sales and profits through new product acceptance and name recognition in the professional and home testing markets. Earlier this month, the company announced expanded distribution of its new Conceive(TM) One-Step ovulation prediction test after Walgreens Stores agreed to carry it in their 1,800 store chain.
 QUIDEL Corp. develops, manufactures and markets rapid immunodiagnostic products that provide simple, accurate and cost- effective diagnoses in the areas of human fertility, infectious disease, allergy and autoimmune disorders. These tests are designed for use in the physician's office, clinical laboratory and home testing markets.
 QUIDEL CORP.
 Comparative Financial Data
 (In thousands, except per share data)
 Three months ended
 Sept. 30,
 FY 1993 FY 1992
 Net sales $6,438 $5,933
 Contract and other revenue $373 $126
 Gross profit $3,116 $2,793
 Operating expenses $3,129 $2,669
 Net income (loss) $235 $168
 Net income (loss) per share $0.01 $0.01
 Six months ended
 Sept. 30,
 FY 1993 FY 1992
 Net sales $12,056 $12,437
 Contract and other revenue $528 $485
 Gross profit $5,702 $5,696
 Operating expenses $6,102 $5,829
 Net income (loss) ($96) $215
 Net income (loss) per share ($0.01) $0.01
 -0- 10/28/92
 /CONTACT: Scott L. Glenn, chairman and CEO, 619-552-7900, or Mark Francois, manager of investor relations, 619-552-7931, both of QUIDEL/
 (QDEL) CO: QUIDEL Corp. ST: California IN: MTC SU: ERN


JL-JB -- SD001 -- 5773 10/28/92 08:01 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 28, 1992
Words:543
Previous Article:"RESTAURANT ROW" CAPTURES CAPE AWARD FOR BEST OVERALL TELEVISION SERIES
Next Article:SPI AND BOEHRINGER INGELHEIM ANNOUNCE EXCLUSIVE AGREEMENT FOR DISTRIBUTION OF SPI'S VIRAZOLE IN GERMANY
Topics:


Related Articles
QUIDEL REPORTS FIRST QUARTER RESULTS
QUIDEL REPORTS INCREASED THIRD QUARTER SALES
QUIDEL SAYS ITS RAPID H. PYLORI TESTSHOULD BENEFIT FROM NIH ANNOUNCEMENT
QUIDEL REPORTS RECORD FIRST QUARTER SALES AND EARNINGS
QUIDEL Reports First Quarter Fiscal 1999 Results
QUIDEL Joins Merck-Medco in Peptic Ulcer Disease Pilot Program.
Quidel Reports First Quarter Fiscal Year 2000 Financial Results.
Quidel Comments on Earnings Outlook and Milestone Payment From Sumitomo.
Quidel Reports Second Quarter Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters